½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1444596

¼¼°è ³»½Ã°æ ±â±â ½ÃÀå : ½ÃÀå Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Global Endoscopy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°è ³»½Ã°æ ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 376¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2029³â±îÁö 517¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø±â°£(2024³â-2029³â) µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.56%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ³»½Ã°æ Àåºñ - ½ÃÀå

COVID-19´Â ¼±ÅÃÀû ¼ö¼úÀ» Ãë¼ÒÇÏ¿© ³»½Ã°æ Àåºñ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ±×·¯³ª ±ÔÁ¦°¡ ÇØÁ¦µÇ°í ³»½Ã°æ ¼ö¼úÀÌ Àç°³µÈ ÀÌÈÄ Áö³­ 2³â°£ ½ÃÀåÀº ȸº¹µÇ¾ú½À´Ï´Ù. Çõ½ÅÀûÀÎ ³»½Ã°æ Àåºñ¸¦ Ãâ½ÃÇÏ°í Ä¡·á¸¦ ÃËÁøÇÏ´Â ½ÃÀå °ü°èÀÚÀÇ Àü·«Àû ³ë·ÂÀ¸·Î À¯Çà Èı⠽ÃÀåÀÇ ¼ºÀåÀ» º¸¿Ï ÇÒ ¼öÀÖ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù, ÈÄÁö Çʸ§Àº ¸ð¹ÙÀÏ ±³À° Çãºê EndoRunner Åõ¾î¸¦ ½ÃÀÛÇÏ°í EndoRunner´Â À¯·´ ¼ÒÈ­±â ³»½Ã°æ ÇÐȸÀÇ ÄÁÆÛ·±½º¿¡¼­ À¯·´ÀÇ º´¿ø°ú ÄÁÆÛ·±½º¸¦ ¹æ¹®ÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ ½ÃÀÛÀº ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿° ÈÄ ³»½Ã°æ °Ë»çÀÇ °úÁ¦¸¦ ´Ù·ç´Â °ÍÀ» ¸ñÇ¥·ÎÇß½À´Ï´Ù. COVID-19 ±ÕÁÖÀÇ »õ·Î¿î µ¹¿¬º¯ÀÌ ±ÕÁÖÀÇ ÃâÇöÀº ³»½Ã°æ Àåºñ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀÌ ¸Å¿ì ÀûÀ» °ÍÀ¸·Î ¿¹»óµÇ¾ú½À´Ï´Ù. ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¾ÈÁ¤ÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¾ú½À´Ï´Ù.

´Ù¾çÇÑ ¸¸¼º Áúȯ ¹× ±âŸ Áúº´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ¹× Áø´ÜÀ» À§ÇÑ ³»½Ã°æ °Ë»çÀÇ Ã¤¿ëÀÌ Áõ°¡ÇÏ¿© ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù¿¡ ¹ßÇ¥µÈ ¿µ±¹ ½ÉÀåÀç´Ü(BHF)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, 2021³â¿¡ ¼¼°èÀûÀ¸·Î ¿µÇâÀ» ¹ÞÀº °¡Àå ÈçÇÑ ½ÉÀåÁúȯÀº °ü»óµ¿¸Æ(ÇãÇ÷¼º) ½ÉÀåÁúȯ, ¸»Ãʵ¿¸Æ Áúº´, ³úÁ¹Áß, ½É¹æ ¼¼µ¿À̾ú½À´Ï´Ù. µû¶ó¼­ ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ãÀÌ Ä¿¼­ Áø´Ü ÀýÂ÷¿¡ ´ëÇÑ ³»½Ã°æ ÀýÂ÷¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ô´Ù°¡ ¼¼°èÀûÀ¸·Î ³·Àº ħ½À ¼ö¼úÀÇ Á߿伺, ä¿ë ¹× ÁøÈ­°¡ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ±× ¿µÇâÀÌ È¯ÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ²ÙÁØÈ÷ È°¿ëµÇ°í ÀÖÀ½À» ÀÔÁõÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 3¿ù¿¡ ¹ßÇ¥µÈ 'ÆÒµ¥¹Í Áß Àúħ½À ¼ö¼ú ¼­ºñ½º À¯Áö'¶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡ µû¸£¸é, ÀÌȯÀ² °¨¼Ò ¹× ȸº¹ ½Ã°£ ´ÜÃà µîÀÇ ÀÌÁ¡À¸·Î ÀÎÇØ Àúħ½À ¼ö¼ú(MIS)Àº ´ëºÎºÐÀÇ º¹ºÎ ¹× º¹ºÎ Áúȯ¿¡¼­ ¼±È£µÇ´Â ¼ö¼úÀÎ °æ¿ì°¡ ¸¹´Ù´Â °ÍÀÔ´Ï´Ù. °ñ¹Ý ¼ö¼ú. ÀÌ·¯ÇÑ MIS ä¿ë Áõ°¡´Â Á¶Á÷ÀÇ ¼ö¼ú ¸ð´ÏÅ͸µ¿¡¼­ ³»½Ã°æ Àåºñ ä¿ë Áõ°¡·Î À̾îÁ® ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.

°Ô´Ù°¡, ³»½Ã°æ Àåºñ Á¦Á¶¾÷üµéÀº ¶ÇÇÑ ±â¼úÀûÀ¸·Î ÷´Ü ³»½Ã°æ ½Ã½ºÅÛ °³¹ß¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀÌ°í ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ ÃËÁøµË´Ï´Ù. ¿¹¸¦ µé¾î, ÈÄÁöÇʸ§ÇコÄɾî´Â 2021³â 11¿ù »óÀ§ ¹× ÇϺΠ¼ÒÈ­°ü ¿ëµµ·Î ¹Ì±¹ ½ÄÇ°ÀǾ౹ÀÇ Àΰ¡¸¦ ¹Þ´Â µà¾ó ä³Î ³»½Ã°æÀ» Ãâ½ÃÇß½À´Ï´Ù. ¶ÇÇÑ, 2022³â 6¿ù¿¡ GetingeÀº ´õ ³ôÀº ¼öÁØÀÇ µðÁöÅÐ ¿¬°á ¹× µ¥ÀÌÅÍ °ü¸®¸¦ Ư¡À¸·Î ÇÏ´Â ED-Flow ÀÚµ¿ ³»½Ã°æ Àçó¸® ÀåÄ¡ÀÇ ¾÷µ¥ÀÌÆ®µÈ ¹öÀüÀ» GetingeÀÇ ³»½Ã°æ Àçó¸® °í°´À» À§ÇØ Ãâ½ÃÇß½À´Ï´Ù. Çß½À´Ï´Ù. À̸¦ ÅëÇØ °¡µ¿ ½Ã°£À» Çâ»ó½ÃÅ°°í »ý»ê¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

µû¶ó¼­ ¸¸¼ºÁúȯ ºÎ´ãÀÇ ³ôÀÌ, ±â¼ú Áøº¸ Áõ°¡, ½ÃÀå±â¾÷ Ãâ½Ã µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ³»½Ã°æ ±â±â ½ÃÀåÀº ¿¹Ãø±â°£ µ¿¾È ¼¼°èÀûÀ¸·Î Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¼÷·ÃµÈ ±â¼úÀÚÀÇ ºÎÁ·°ú ¼Ò¼öÀÇ ³»½Ã°æÀ¸·Î ÀÎÇÑ °¨¿°ÀÌ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÏ°í ÀÖ½À´Ï´Ù.

³»½Ã°æ ±â±â ½ÃÀå µ¿Çâ

¿¬¼º ³»½Ã°æ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ´õ ³ªÀº ¼ºÀåÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¬¼º ³»½Ã°æÀº ºûÀ» Àü´ÞÇÏ°í °üÂûÀÚ¿¡°Ô À̹ÌÁö¸¦ Àü´ÞÇÏ´Â ±¤ÇÐ ÀåºñÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Àåºñ¿¡´Â À¯¿¬ÇÑ Åõ¸í ¼¶À¯°¡ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®Àº ´Ù¸¥ ´ëüǰ¿¡ ºñÇØ Á¦°øµÇ´Â ÀåÁ¡, »ó½Ã Áõ°¡, ¿¬¼º ³»½Ã°æ äÅà Áõ°¡·Î ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿°Áõ¼º Àå Áúȯ(IBD), À§¾Ï, °áÀå¾Ï, È£Èí±â °¨¿°, È£Èí±â Á¾¾ç µî ´Ù¾çÇÑ ¸¸¼º ÁúȯÀÇ °æ¿ì Áø´Ü ¸ñÀûÀ¸·Î ³»½Ã°æÀ» ±¤¹üÀ§ÇÏ°Ô »ç¿ëÇØ¾ß ÇÕ´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Áúº´ÀÇ ÀÌȯÀ²ÀÌ ³ô¾ÆÁö¸é ¿¬¼º ³»½Ã°æ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¾ÏÇùȸÀÇ 2023³â º¸°í¼­¿¡ µû¸£¸é 2022³â ¹Ì±¹¿¡¼­ ÃßÁ¤ 26,380¸íÀÇ »õ·Î¿î À§¾ÏÀÌ Áø´ÜµÇ°í 2023³â¿¡´Â 26,500¸íÀÇ »õ·Î¿î À§¾ÏÀÌ Áø´ÜµÉ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¸¸¼º ÁúȯÀÇ ¹ß»ý·üÀº ³ô½À´Ï´Ù. ±×¸®°í ±× º¸±ÞÀ¸·Î ¿¬¼º ³»½Ã°æ ¼ö¿ä°¡ ±ÞÁõÇÏ°í ÀÖ½À´Ï´Ù.

°Ô´Ù°¡ ½ÃÀå°ü°èÀÚ¿¡ ÀÇÇÑ »ó½Ã¿Í ½ÂÀÎÀº ¿¹Ãø±â°£ µ¿¾È ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 8¿ù º¸½ºÅÏ °úÇÐÀº EXALT ¸ðµ¨ B ´ÜÀÏ »ç¿ë ±â°üÁö°æÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. EXALT ¸ðµ¨ B ÀÏȸ¿ë ±â°üÁö°æÀº À¯¿¬ÇÑ ±â°üÁö°æÀÇ ÃֽŠÁøÈ­ ¹öÀüÀÔ´Ï´Ù. ICU¿¡¼­ »ç¿ëÇϱâ À§ÇØ °³¹ßµÇ¾úÀ¸¸ç ÀÌÁß ·ç¸à Æ©ºê ¹èÄ¡¿Í °°Àº º¹ÀâÇÑ È£Èí °úÁ¤ Áß¿¡±âµµ¸¦ ±ú²ýÇÏ°Ô À¯ÁöÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

µû¶ó¼­ Áúº´ È®»ê Áõ°¡, ¿¬¼º ³»½Ã°æÀÇ ¸î °¡Áö ÀåÁ¡ ¹× Á¦Ç° Ãâ½Ã´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ºÎ¹® ¼ºÀåÀ» ¿¹»óÇÕ´Ï´Ù.

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ½ÃÀå Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

½ÉÇ÷°üÁúȯ, °áÀåÁ÷Àå¾Ï, À§¾Ï µîÀÇ ³ôÀº Áúȯ, Àúħ½À ¼ö¼ú ä¿ë Áõ°¡, ±â¼ú Çõ½Å, ½ÂÀÎ, Á¦Ç° Ãâ½Ã, ½ÃÀå °ü°èÀÚÀÇ ÆÄÆ®³Ê½Ê µîÀÌ ÀÌ Áö¿ªÀÇ ³»½Ã°æ ½ÃÀåÀ» °ßÀÎÇÑ´Ù°í ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù¿¡ Cedars-Sinai°¡ ¾÷µ¥ÀÌÆ®ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é, °ü»óµ¿¸Æ ¿ìȸ ¶Ç´Â ¿ìȸ ¼ö¼ú·Îµµ ¾Ë·ÁÁø °ü»óµ¿¸Æ ¿ìȸ ÀÌ½Ä ¼ö¼ú(CABG)ÀÌ °¡Àå ÀϹÝÀûÀÎ ½ÉÀå ¼ö¼úÀ̸ç, 30¸¸ ¸í ÀÌ»óÀÌ ¿ìȸ ¼ö¼ú ¿¡ ¼º°øÇÑ °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù. ¸Å³â ¹Ì±¹¿¡¼­. ¹ÙÀÌÆнº ¼ö¼úÀÇ ¼ö°¡ ¸¹±â ¶§¹®¿¡ ¿µ»ó À¯µµ ¼ö¼ú ½Ã½ºÅÛ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ±¹³» ³»½Ã°æ ±â±âÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

°Ô´Ù°¡ À§Àå¾Ï°ú °áÀåÁ÷Àå¾ÏÀÇ Á¶±â Áø´ÜÀ» À§ÇÑ ³»½Ã°æ ¼ö¼ú Áõ°¡·Î ÇâÈÄ ¼ö³â°£ ½ÃÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ëºÎºÐÀÇ À§Àå°ü °£Áú Á¾¾çÀº ´ë°³ Á÷Àå, °áÀå ¹× ½Äµµ¿¡¼­ ¹ß»ýÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹¾ÏÇùȸ(ACS)ÀÇ 2023³â º¸°í¼­¿¡ µû¸£¸é 2023³â¿¡´Â ¹Ì±¹¿¡¼­ 2¸¸1,500¸íÀÌ ½Äµµ¾Ï, 2¸¸6,500¸íÀÌ À§¾Ï, 15¸¸3,000¸íÀÌ °áÀåÁ÷Àå¾ÏÀ¸·Î Áø´ÜÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ ¾ÏÀÇ ºÎ´ãÀÌ Å©±â ¶§¹®¿¡ ¿¹Ãø±â°£ Áß¿¡ ±¹³» ³»½Ã°æ ±â±â ¼ö¿ä°¡ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ Áö¿ªÀÇ ³»½Ã°æ Àåºñ Ãâ½Ã¿Í ½ÂÀÎ Áõ°¡µµ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ÀÏȸ¿ë ³»½Ã°æ °³¹ß ȸ»çÀÎ Zsquare´Â 2022³â 7¿ù¿¡ ÀÚ»ç Á¦Ç°ÀÎ Zsquare ENT-Flex ºñÀÎÈÄ°æÀ» ¹Ì±¹¿¡¼­ ÆǸÅÇϱâ À§ÇÑ ½ÄÇ° ÀǾ౹ 510K Àΰ¡¸¦ ÃëµæÇß½À´Ï´Ù. ¶ÇÇÑ 2022³â 11¿ù¿¡´Â Áø´Ü ¹× Ä¡·á¿ë ³»½Ã°æ ¼Ö·ç¼ÇÀÇ ÀÇ·á ¾÷°è ¸®´õÀÎ PENTAX MedicalÀÌ Ä³³ª´Ù¿¡¼­ ¼º´É ³»½Ã°æ ÃÊÀ½ÆÄ(EUS) ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù.

µû¶ó¼­ Á¦Ç° Ãâ½Ã Áõ°¡¿Í ¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ Àúħ½À ¿µ»óó¸® ¹× ¼ö¼ú ä¿ë Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø±â°£ µ¿¾È ij³ª´Ù ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

³»½Ã°æ Àåºñ »ê¾÷ °³¿ä

½ÃÀåÀº Àû´çÇÑ °æÀïÀÌ ÀÖÀ¸¸ç ¿©·¯ ¼¼°è ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ½ÃÀåÀÌ Áøº¸ÇÔ¿¡ µû¶ó ±â¾÷Àº ¾ÖÇø®ÄÉÀ̼ÇÀ» ±â¹ÝÀ¸·Î ³»½Ã°æ ½Ã½ºÅÛ¿¡¼­ ¸íÈ®ÇÑ Â÷º°È­¸¦ ´Þ¼ºÇÏ·Á°íÇÕ´Ï´Ù. ÁÖ¿ä ½ÃÀå ±â¾÷Àº Boston Scientific Corporation, Medtronic PLC, Olympus Corporation, Cook Group Incorporated ¹× Johnson & JohnsonÀÔ´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù ¾Ö³Î¸®½ºÆ® ¼­Æ÷Æ®

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³·Àº ħ½À ¼ö¼ú¿¡ ´ëÇÑ °ü½É Áõ°¡
    • Ä¡·á ¹× Áø´Ü¿¡ À־ÀÇ ³»½Ã°æ °Ë»çÀÇ Ã¤¿ë Áõ°¡
    • ¿ëµµÀÇ °­È­·Î À̾îÁö´Â ±â¼úÀÇ Áøº¸
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·ÃµÈ ±â¼úÀÚÀÇ ºÎÁ·
    • ¼Ò¼öÀÇ ³»½Ã°æ¿¡ ÀÇÇÑ °¨¿°Áõ
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ´ëü Á¦Ç°ÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°èÀÇ °Ý·Ä

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • µð¹ÙÀ̽ºÀ¯Çüº°
    • ³»½Ã°æ
      • °æ¼º ³»½Ã°æ
      • ¿¬¼º ³»½Ã°æ
      • ĸ½¶ ³»½Ã°æ
      • ·Îº¿ Áö¿ø ³»½Ã°æ
    • ³»½Ã°æ ¼ö¼ú ÀåÄ¡
      • °ü°³/ÈíÀÔ ½Ã½ºÅÛ
      • ¾×¼¼½º µð¹ÙÀ̽º
      • »óó ÇÁ·ÎÅØÅÍ
      • ±âº¹ÀåÄ¡
      • ¼öµ¿Á¶À۱ⱸ
      • ±âŸ ³»½Ã°æ ¼ö¼ú ±â±¸
    • ½Ã°¢È­ ÀåÄ¡
      • ³»½Ã°æ Ä«¸Þ¶ó
      • SD ½Ã°¢È­ ½Ã½ºÅÛ
      • HD ºñÁÖ¾ó¶óÀÌÁ¦ÀÌ¼Ç ½Ã½ºÅÛ
  • ¿ëµµº°
    • ¼ÒÈ­±â°ú
    • È£Èí±â°ú
    • Á¤Çü¿Ü°ú
    • ½ÉÀ庴ÇÐ
    • À̺ñÀÎÈÄ°ú ¼ö¼ú
    • ºÎÀΰú
    • ½Å°æ³»°ú
    • ±âŸ ¿ëµµ
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Boston Scientific Corporation
    • Commed Corporation
    • Cook Group Incorporated
    • Richard Wolf GmbH
    • Johnson &Johnson
    • Fujifilm Holdings Corporation
    • Medtronic PLC
    • Olympus Corporation
    • Karl Storz SE &Co. KG
    • Stryker Corporation
    • Hoya Corporation
    • Smith &Nephew PLC

Á¦7Àå ½ÃÀå ±âȸ¿Í ¹Ì·¡ µ¿Çâ

BJH 24.03.15

The Global Endoscopy Devices Market size is estimated at USD 37.63 billion in 2024, and is expected to reach USD 51.70 billion by 2029, growing at a CAGR of 6.56% during the forecast period (2024-2029).

Global Endoscopy Devices - Market

COVID-19 impacted the endoscopy devices market due to the cancellations of elective procedures. However, the market recovered in the last two years since the restrictions were lifted and endoscopic procedures resumed. The strategic initiatives by market players to launch innovative endoscopic devices and boost the procedures compensated for the market growth in the later phase of a pandemic. For instance, in April 2022, Fujifilm launched a mobile training hub EndoRunner Tour, with the EndoRunner set to visit hospitals and conferences across Europe at the European Society of Gastrointestinal Endoscopy conference. The launch intended to tackle endoscopy challenges in post-COVID infection. The emergence of new variants of COVID-19 strains was expected to have a negligible impact on the endoscopy devices market. The market was expected to grow stable during the forecast period.

The rising prevalence of various chronic diseases and other diseases is expected to raise the adoption of endoscopy for treatment and diagnosis, thereby boosting the market's growth over the forecast period. For instance, the British Heart Foundation (BHF) data published in January 2022 reported that in 2021, the most common heart conditions affected globally were coronary (ischemic) heart disease, peripheral arterial disease, stroke, and atrial fibrillation. Thus, the high burden of cardiovascular diseases is further expected to increase the demand for endoscopy procedures for diagnostic procedures, thereby boosting the market's growth.

Furthermore, the growing significance, adoption, and evolution of minimally invasive surgeries worldwide testify to the impact that is steadily being utilized for improving patient outcomes. For instance, according to the study titled 'Maintaining a minimally invasive surgical service during a pandemic' published in March 2022, because of benefits including decreased morbidity and quicker recovery times, minimally invasive surgery (MIS) is frequently the preferred procedure for most abdominal and pelvic surgeries. Such a rise in the adoption of MIS will lead to increased adoption of endoscopy devices during the surgical monitoring of tissues, driving the market growth.

Additionally, manufacturers of endoscopy devices are also increasingly focusing on developing technologically advanced endoscopy systems, thereby boosting market growth over the forecast period. For instance, in November 2021, FUJIFILM Healthcare launched the dual-channel endoscope to be cleared by the United States Food and Drug Administration for upper and lower gastrointestinal applications. Also, in June 2022, Getinge released an updated version of the ED-Flow automated endoscope reprocessor featuring a higher level of digital connectivity and data management to Getinge's endoscope reprocessing customers, which will result in improved uptime and increased productivity.

Thus, owing to factors such as the high burden of chronic diseases, rising technological advancements, and launches by market players, the endoscopy devices market is expected to show significant growth globally over the forecast period. However, the lack of skilled technicians and infections caused by few endoscopes hinder the market growth.

Endoscopy Devices Market Trends

The Flexible Endoscope Segment is Expected to Show Better Growth in the Forecast Period

A flexible endoscope is an optical instrument that transmits light and carries images back to the observer. Furthermore, these instruments are equipped with flexible transparent fibers. The segment is expected to grow during the forecast period due to the advantages offered over other alternatives, rising launches, and increasing adoption of flexible endoscopes.

Various chronic diseases such as inflammatory bowel diseases (IBD), stomach cancer, colon cancer, respiratory infections, respiratory tumors, and others require extensive use of endoscopes for diagnostic purposes. Thus, the high prevalence of these diseases leads to a surge in demand for flexible endoscopes. For instance, according to the American Cancer Society 2023 report, an estimated 26,380 new cases of stomach cancer were diagnosed in the United States in 2022, and 26,500 new stomach cancer are estimated to be diagnosed in 2023. Thus, these chronic diseases' high incidence and prevalence lead to a surge in demand for flexible endoscopes.

Furthermore, the launches and approvals by market players are expected to propel the segment's growth during the forecast period. For instance, in August 2021, Boston Scientific received FDA approval for the EXALT Model B Single-Use Bronchoscope. EXALT Model B Single-Use Bronchoscope is the latest evolution in flexible bronchoscopy. It is developed for use in ICU and built to help keep airways clear during complex respiratory procedures like double-lumen tube placements.

Thus, considerable segment growth is expected over the forecast period due to the increasing prevalence of diseases, several advantages of a flexible endoscope, and product launches.

North America is Expected to Hold a Significant Market Share Over The Forecast Period

The high burden of diseases such as cardiovascular diseases, colorectal and stomach cancer, increasing adoption of minimally invasive surgeries, technological innovations, approvals, product launches, and partnerships by market players are expected to drive the endoscopy market in the region. For instance, the data updated by Cedars-Sinai in January 2022 reported that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass or bypass surgery, is the most common heart surgery and more than 300 thousand people have successful bypass surgery in the United States each year. The high number of bypass surgery performed may cause an increased demand for image-guided surgical systems, thus driving the growth of endoscopy devices in the nation.

Furthermore, an increase in endoscopic procedures for early diagnosis of gastrointestinal and colorectal cancers is expected to boost the market in the coming years. Most gastrointestinal stromal tumors usually start in the rectum, colon, and esophagus. For instance, as per the American Cancer Society (ACS) 2023 report, the expected esophagus cancer is estimated to be diagnosed in 21.5 thousand individuals, stomach cancer in 26.5 thousand individuals, and colorectal cancer in 153 thousand in the United States in 2023. The high burden of these cancers is expected to propel the demand for endoscopy devices in the nation during the forecast period.

The rising launches and approvals of endoscopy devices in the region also contribute to the market growth during the forecast period. For instance, in July 2022, Zsquare, a developer of single-use endoscopes, received Food and Drug Administration 510K clearance to market its product, the Zsquare ENT-Flex Rhinolaryngoscope, in the United States. Also, in November 2022, PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, launched the Performance Endoscopic Ultrasound (EUS) system in Canada.

Thus, the factors such as the rising product launches and the increasing adoption of minimally invasive imaging and surgeries due to chronic diseases are expected to boost the market's growth in Canada during the forecast period.

Endoscopy Devices Industry Overview

The market is moderately competitive and consists of several global players. As the market progresses, the firms try to achieve clear differentiation in endoscopic systems based on their application. The major market players are Boston Scientific Corporation, Medtronic PLC, Olympus Corporation, Cook Group Incorporated, and Johnson & Johnson.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Preference for Minimally-Invasive Surgeries
    • 4.2.2 Increasing Adoption of Endoscopy for Treatment and Diagnosis
    • 4.2.3 Technological Advancements Leading to Enhanced Applications
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Technicians
    • 4.3.2 Infections Caused by Few Endoscopes
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Type of Device
    • 5.1.1 Endoscopes
      • 5.1.1.1 Rigid Endoscope
      • 5.1.1.2 Flexible Endoscope
      • 5.1.1.3 Capsule Endoscope
      • 5.1.1.4 Robot-assisted Endoscope
    • 5.1.2 Endoscopic Operative Device
      • 5.1.2.1 Irrigation/Suction System
      • 5.1.2.2 Access Device
      • 5.1.2.3 Wound Protector
      • 5.1.2.4 Insufflation Device
      • 5.1.2.5 Operative Manual Instrument
      • 5.1.2.6 Other Endoscopic Operative Devices
    • 5.1.3 Visualization Equipment
      • 5.1.3.1 Endoscopic Camera
      • 5.1.3.2 SD Visualization System
      • 5.1.3.3 HD Visualization System
  • 5.2 By Application
    • 5.2.1 Gastroenterology
    • 5.2.2 Pulmonology
    • 5.2.3 Orthopedic Surgery
    • 5.2.4 Cardiology
    • 5.2.5 ENT Surgery
    • 5.2.6 Gynecology
    • 5.2.7 Neurology
    • 5.2.8 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Conmed Corporation
    • 6.1.3 Cook Group Incorporated
    • 6.1.4 Richard Wolf GmbH
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Fujifilm Holdings Corporation
    • 6.1.7 Medtronic PLC
    • 6.1.8 Olympus Corporation
    • 6.1.9 Karl Storz SE & Co. KG
    • 6.1.10 Stryker Corporation
    • 6.1.11 Hoya Corporation
    • 6.1.12 Smith & Nephew PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦